NCT05882032

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

A Phase 1, Multicenter, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Hepatic Function and Participants With Mild, Moderate, or Severe Hepatic Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of LY3502970 will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.

Conditions

• Healthy
• Hepatic Insufficiency

Interventions

Type	Name	Description
DRUG	LY3502970	Administered orally.

Timeline

• Start date: 2023-06-13
• Primary completion: 2024-11-18
• Completion: 2024-11-18
• First posted: 2023-05-31
• Last updated: 2024-12-03

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study